The FDA is cautious about solely relying on real-world evidence for drug label indications but supports experiments to bridge the gap, as demonstrated by a pilot project initiated by the Friends of Cancer Research, aiming to establish best practices and standards for incorporating real-world evidence into drug development and regulatory decision-making processes.
Read More
Read More